Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Zengerling, Friedemann  [Clear All Filters]
2022
Pfister D, Oechsle K, Schmidt S, Busch J, Bokemeyer C, Heidenreich A, Heinzelbecker J, Ruf C, Winter C, Zengerling F, et al. First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group. World J Urol. 2022.
Melzer MKarl, Breunig M, Arnold F, Wezel F, Azoitei A, Roger E, Krüger J, Merkle J, Schütte L, Zehe V, et al. Organoids at the PUB: The Porcine Urinary Bladder serves As A Pancreatic Niche for Advanced Cancer Modelling. Adv Healthc Mater. 2022:e2102345.
2023
Zschäbitz S, Biernath N, Hilser T, Höllein A, Zengerling F, Cascucelli J, Paffenholz P, Seidl D, Lutz C, Schlack K, et al. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort. Eur Urol Open Sci. 2023;53:31-37.
Wang X, Liu J, Azoitei A, Eiseler T, Meessen S, Jiang W, Zheng X, Makori AW, Eckstein M, Hartmann A, et al. Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics. Cell Mol Life Sci. 2023;80(10):299.
2024
Klümper N, Tran NKhanh, Zschäbitz S, Hahn O, Büttner T, Roghmann F, Bolenz C, Zengerling F, Schwab C, Nagy D, et al. Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. J Clin Oncol. 2024:JCO2301983.